

# Short-term evaluation of a commercial eyedrop in contact lens wearers

<b>Submission date</b> 20/02/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/03/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 08/03/2019	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This is an early feasibility study to gain preliminary insights into the retention time of a commercial eyedrop in contact lens wearers.

### Who can participate?

Healthy, adapted contact lens wearers 18 years of age and older are eligible to participate.

### What does the study involve?

Following a screening appointment to confirm eligibility, all eligible study participants will be asked to instill two different commercial eye drops with their contact lenses using three different regimens (i.e. one to four times per day at different time points during the day), on three different days. Each study day will be separated by a minimum of 1 day and a maximum of 10 days.

### What are the possible benefits and risks of participating?

There might not be direct benefits to the participants in this study. However, participation may contribute to scientific research information that may be used in the development of new contact lens products. The risks to participants in this study are similar to those associated with normal daily wear of soft contact lenses.

### Where is the study run from?

This study will be run at one site: Visioncare Research Clinic in Farnham, United Kingdom.

### When is the study starting and how long is it expected to run for?

The study is planned to start in June 2017 and is expected to run for approximately 2 months.

### Who is funding the study?

The study is funded by CooperVision, Inc.

### Who is the main contact?

Nancy Keir, [nkeir@coopervision.com](mailto:nkeir@coopervision.com)

# Contact information

## Type(s)

Scientific

## Contact name

Dr Nancy Keir

## Contact details

5870 Stoneridge Dr, Suite 1  
Pleasanton  
United States of America  
94588  
925-730-6768  
nkeir@coopervision.com

# Additional identifiers

## Clinical Trials Information System (CTIS)

N/A

## ClinicalTrials.gov (NCT)

N/A

## Protocol serial number

CV-16-58

# Study information

## Scientific Title

Crossover evaluation of Clinitas Soothe® eye drops in symptomatic soft contact lens wearers (part 1)

## Acronym

N/A

## Study objectives

The test product will provide non-inferior subjective comfort and pre-lens tear stability compared to the control product.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 12/06/2017, North East - Newcastle & North Tyneside 1 Research Ethics Committee (Jarrow Business Centre, Rolling Mill Road, Jarrow, NE32 3DT; 0207 104 8117), ref: 17/NE/0094.

## Study design

Single site, 3-day, contralateral, randomised, single-masked, early feasibility study.  
The order of the study products will be determined randomly.

## **Primary study design**

Interventional

## **Study type(s)**

Other

## **Health condition(s) or problem(s) studied**

N/A

## **Interventions**

This was a feasibility study to evaluate the retention time of a polymer on the eye in order to provide insights into new product development programs. Each commercial eyedrop was used by all subjects according to three different regimens/schedules. The regimens/schedules were assigned randomly over three study days. Each study day was separated by a minimum of 1 day and a maximum of 10 days.

## **Intervention Type**

Device

## **Primary outcome(s)**

Measured on each study day:

1. Monocular comfort [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.
2. Pre-lens Non-invasive break-up time (NIBUT) [s] will be measured using a Keeler Tearscope.

## **Key secondary outcome(s)**

Measured on each study day:

1. Subjective dryness [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.
2. Subjective vision quality [1-100, in 1 unit steps] will be measured using a Visual Analog Scale.
3. Lens preference for comfort [R/L, Likert 1-5] will be measured using a Likert Scale.
4. Ocular health (limbal hyperaemia and corneal staining) will be measured using a slit lamp microscope.

## **Completion date**

07/08/2017

# **Eligibility**

## **Key inclusion criteria**

1. ≥18 years of age
2. Adapted and current symptomatic soft CL wearers (i.e. >1 month of wear)
3. Spherical spectacle prescription between +6.00 and -10.00D (inclusive)
4. Correctable to 6/12 (20/40) or better in each eye
5. Require visual correction in both eyes (monovision allowed but no monofit)
6. Have normal eyes with no evidence of any ocular abnormality or disease.

## **Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

15

**Key exclusion criteria**

1. Previously shown sensitivity to any of the study solutions' components.
2. Any systemic or ocular disease or allergies affecting ocular health.
3. Using systemic or topical medications that will, in the investigator's opinion, affect ocular physiology or lens performance.
4. Clinically significant (>Grade 3) corneal stromal edema, corneal vascularisation, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
5. Any corneal infiltrates or any corneal scarring or neovascularization within the central 5mm of the cornea.
6. Keratoconus or other corneal irregularity.
7. Aphakia or amblyopia.
8. Has diabetes.
9. Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
10. History of chronic eye disease (e.g. glaucoma or ARMD).
11. Pregnant or lactating or planning a pregnancy at the time of enrolment.
12. Participation in any concurrent clinical trial or in last 14 days.

**Date of first enrolment**

16/06/2017

**Date of final enrolment**

01/07/2017

**Locations**

**Countries of recruitment**

United Kingdom

England

## Study participating centre

### Visioncare

Craven House, Arundell Place, West Street  
Farnham  
United Kingdom  
GU9 7EN

## Sponsor information

### Organisation

CooperVision Inc. (USA)

## Funder(s)

### Funder type

Industry

### Funder Name

CooperVision, Inc.

## Results and Publications

### Individual participant data (IPD) sharing plan

There are no plans for publication or to make the dataset available.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes